Minimal Change Disease Recurrence and Management

Introduction to Recurrence Rates

• More than half of all patients with minimal change disease who initially respond to steroids will experience relapses, with recurrence rates ranging from 34% to 85% in adults and up to 71% in children, according to the Kidney International guidelines 1, 2

Risk Factors for Relapse

• Shorter initial treatment duration (less than 12 weeks of corticosteroids) is a key predictor that increases relapse risk 3
• Monotherapy with corticosteroids alone versus combined treatment with cyclophosphamide is associated with a higher risk of relapse 4

Management of Relapses

• Restart the same corticosteroid regimen that induced initial remission, with a dose of prednisone 1 mg/kg/day (maximum 80 mg) or 2 mg/kg alternate-day (maximum 120 mg), and maintain high-dose for minimum 4 weeks if remission achieved 3
• Steroid-sparing agents, such as cyclophosphamide, calcineurin inhibitors, and mycophenolate mofetil, are indicated to avoid cumulative corticosteroid toxicity in patients with frequent relapses or steroid dependency 1, 2, 3, 5

Steroid-Sparing Agents

• Cyclophosphamide achieves longer remissions in frequently relapsing patients compared to steroid-dependent patients, but has a major limitation of cumulative gonadal toxicity and oncogenicity risk 1
• Calcineurin inhibitors, such as cyclosporine and tacrolimus, can achieve complete remission in 73-82% of steroid-dependent adults, but require careful monitoring of serum creatinine and potential nephrotoxicity 3, 4, 5
• Mycophenolate mofetil is reserved for patients intolerant of corticosteroids, cyclophosphamide, and CNIs, but has lower evidence quality compared to other agents 3, 5, 6

Monitoring During Long-Term Therapy

• For patients on CNIs beyond 12 months, monitor serum creatinine closely and discontinue if creatinine rises >30% above baseline and doesn't plateau after dose reduction 4, 5
• Consider repeat renal biopsy at 12-24 months to assess for CNI nephrotoxicity, especially if creatinine elevated or maintenance dose >3.5 mg/kg/day 4

Monitoring Strategies for Minimal Change Disease Post‑Remission

Active Treatment Monitoring

• Monthly clinical assessments are recommended for patients with high or moderate disease activity who are undergoing treatment adjustments, according to a Kidney International study. 7
• Complete remission is typically achieved within 4–16 weeks after initiating corticosteroid therapy, as reported in the same Kidney International source. 7

Post‑Remission Follow‑Up (KDIGO Guidelines)

• Patients in sustained remission should be seen every 3–6 months to detect early relapse while avoiding unnecessary healthcare utilization; this interval is endorsed by the KDIGO guidelines. 7
• Extending the monitoring interval beyond 6 months in patients with sustained remission may miss early relapses, reducing the effectiveness of timely intervention. 7

Long‑Term Immunosuppression Surveillance

• For individuals maintained on calcineurin inhibitors for >12 months, serum creatinine should be closely monitored, and a repeat renal biopsy considered at 12–24 months if creatinine rises >30 % above baseline or if the maintenance dose exceeds 3.5 mg/kg/day, to assess for CNI‑related nephrotoxicity. 8

Monitoring Frequency Considerations

• The 3–6‑month visit schedule balances early relapse detection with resource use, as highlighted by the KDIGO recommendation. 7

Patient Education & Prompt Reporting

• Patients should be instructed to contact their nephrologist immediately if they notice signs of relapse (e.g., edema, foamy urine) rather than waiting for the next scheduled appointment, to enable rapid management. 7

Follow‑Up and Management of Adults with Childhood‑Onset Minimal Change Disease (MCD)

Long‑Term Prognosis

• In patients who achieved glucocorticoid‑induced remission during childhood, 15‑year patient survival is 83 %–98 % and fewer than 5 % progress to end‑stage renal disease, indicating excellent long‑term kidney survival. 9, 10

Monitoring Recommendations

• At each follow‑up visit (every 3–6 months), serum creatinine and estimated glomerular filtration rate should be measured to assess renal function. 11
• Blood pressure should be checked at every visit because hypertension can develop even in previously normotensive MCD patients. 11

Management of Prior Immunosuppression

• For adults who received calcineurin inhibitors (CNIs) in childhood, serum creatinine must be closely monitored due to the risk of chronic nephrotoxicity. 12, 10
• If creatinine rises >30 % above baseline and does not plateau after dose reduction (or after discontinuation if still on therapy), the CNI should be stopped. 12

Relapse Management

• When a relapse is confirmed, the same corticosteroid regimen that induced the original remission should be restarted, and tapering should begin 2 weeks after complete remission is documented. 9, 10

• For patients with frequent relapses or steroid dependence, steroid‑sparing agents—such as cyclophosphamide, CNIs, mycophenolate mofetil, or rituximab—should be employed to limit cumulative glucocorticoid toxicity. 12

Diagnostic Considerations

• In adults who experience a relapse, a renal biopsy should not be delayed; it is required to differentiate MCD from focal segmental glomerulosclerosis (FSGS), which may present with overlapping clinical features. 12, 9, 10

Medication Recommendations

• Statins should not be used solely to treat hyperlipidemia, and ACE inhibitors/ARBs should not be prescribed solely to lower proteinuria in normotensive patients during remission, as current evidence does not support these interventions for MCD. 13